Business
Organon Completes Divestiture of JADA® System to Laborie
JERSEY CITY, N.J., January 28, 2026--Organon announces the successful closing of the sale of its JADA® System to Laborie Medical Technologies Corp.
About this update from Organon & Co.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/2d3361bc7ab2378962fa1caedc7729aa"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/O9hepyw9_h2ZSSeehgvJ1Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/2d3361bc7ab2378962fa1caedc7729aa","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/apjGPoOeX3O2Ep_yeOQErQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/2d3361bc7ab2378962fa1caedc7729aa","width":1024,"height":512}},"lazy":false},{"type":"text","content":"JERSEY CITY, N.J., January 28, 2026--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today the successful closing of the sale of its JADA® System to Laborie Medical Technologies Corp. Please see our prior announcement for a summary of the transaction terms.","length":372,"tagName":"p"},{"type":"text","content":"Indications for Use","length":19,"tagName":"p"},{"type":"text","content":"The JADA® System is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted.","length":158,"tagName":"p"},{"type":"text","content":"Contraindications","length":17,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Ongoing intrauterine pregnancy","length":30,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Untreated uterine rupture","length":25,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Unresolved uterine inversion","length":28,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Current cervical cancer","length":23,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Known uterine anomaly","length":21,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Current purulent infection of vagina, cervix, or uterus","length":55,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"For C-sections: Cervix <3 cm dilated before use of JADA","length":58,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":240,"olTy...